Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval

SHANGHAI - China's State FDA held a pre-IND meeting June 17 with Shanghai-based Hutchison MediPharma on its Phase I development plan for its solid tumor drug HMPL-012, the company told PharmAsia News

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip